Articles from Moderna, Inc.

New U.S. government contract includes an award up to $1.74 billion for 66 million doses to be delivered in 2022; additional options, if exercised, may raise total to 300 million doses

CAMBRIDGE, MA / ACCESSWIRE / July 22, 2022 / Moderna, Inc. (NASDAQMRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending a variation to the conditional marketing authorization (CMA) to include a booster dose of Spikevax, the Company's COVID-19 vaccine, at the 50 µg dose level for adolescents (12-17 years) at least three months after completion of the primary series.

Announcement follows recent authorization of the Company's mRNA COVID-19 vaccine in Argentina, Canada, Israel, the US, and Taiwan for active immunization to prevent COVID-19 caused by SARS-CoV-2 in children aged 6 months to five years

Two-dose series takes one month to complete, with similar vaccine efficacy estimates against Omicron to those seen in adults

CAMBRIDGE, MA / ACCESSWIRE / July 13, 2022 / Moderna, Inc. (NASDAQMRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, August 3, 2022 to report its second quarter 2022 financial results, and provide a corporate update.

Moderna advances global health commitment with mRNA vaccine candidate against the Nipah virus, a lethal pathogen with pandemic potential

mRNA-1273.214 has now demonstrated significantly higher antibody titers against all tested variants, including Omicron BA.1 and BA.4/5 subvariants, ancestral virus, Alpha, Beta, Delta, and Gamma

mRNA-1273.214 Exhibited a Greater Than 5-Fold Boost in Neutralizing Antibodies Against BA.4 and BA.5 Subvariants in Phase 2/3 Study

Manufacturing facility would provide access to domestically manufactured vaccines against respiratory viruses

mRNA-1273 was authorized for children and adolescents aged 6 months through 17 years of age, administered as two doses given one month apart

Data Show Significantly Higher Geometric Mean Titer Ratios, Meeting Prespecified Endpoints for Superiority Against Omicron Variant

mRNA-1010 is Moderna's first seasonal influenza vaccine candidate to enter a Phase 3 trialmRNA-1010 is one of several influenza vaccine candidates being developed in Moderna's respiratory portfolioModerna now has four programs in Phase 3 studies: Omicron-containing bivalent COVID booster, influenza, RSV, CMV

CAMBRIDGE, MA / ACCESSWIRE / June 2, 2022 / Moderna, Inc.(NASDAQMRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced an agreement with the European Commission (EC) to amend their originally agreed contractual delivery schedules for the Moderna COVID-19 vaccine booster product (Spikevax, mRNA-1273) or updated booster vaccine candidate.

CAMBRIDGE, MA / ACCESSWIRE / June 1, 2022 / Moderna, Inc. (NASDAQMRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in the following upcoming investor conferences:

Moderna to become marketing authorization holder in Japan and be responsible for all import, local regulatory, development, quality assurance, and commercial activities for SpikevaxTM from August 1, 2022

CAMBRIDGE, MA / ACCESSWIRE / May 18, 2022 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in a fireside chat at the UBS 2022 Global Healthcare Conference on Tuesday, May 24th at 9:15 a.m. ET. A live webcast of the presentation will be available under "Events and Presentations" in the Investors section of the Moderna website at

Phase I trial in Rwanda and South Africa aims to evaluate mRNA HIV vaccine antigen for safety and immunogenicity and strengthen regional scientific capacity NEW YORK, NY and CAMBRIDGE, MA / ACCESSWIRE / May 18, 2022 / The nonprofit scientific research organization IAVI and Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the first participant screenings are soon

Moderna continues to expand its mRNA platform for a range of additional clinical applications and routes of administration including a modality for lung delivery Moderna's 5th Annual Science and Technology Day presentations highlight continued focus, safety and innovation of our intramuscular lipid nanoparticles (LNPs) delivery system in vaccines CAMBRIDGE, MA / ACCESSWIRE / May 17, 2022 / Moderna, Inc. (NASDAQMRNA), a biotechnology company

CAMBRIDGE, MA / ACCESSWIRE / May 9, 2022 / Moderna, Inc. (NASDAQMRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that that it will host its in-person Science and Technology Day for analysts and investors at 9:00 a.m. ET on Tuesday, May 17 in Boston, MA. Moderna's Science and Technology Day will feature presentations from Stephen Hoge M.D., President, Melissa Moore Ph.D., Chief Scientific

Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.

Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.

Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.

Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.

CAMBRIDGE, MA / ACCESSWIRE / April 27, 2022 / Moderna, Inc., (NASDAQMRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Arpa Garay will join Moderna as Chief Commercial Officer, effective Monday, May 31, 2022. She will serve on Moderna's Executive Committee and report to Chief Executive Officer, Stéphane Bancel. "I am very pleased to welcome Arpa to Moderna as our Chief Commercial

Moderna's first bivalent booster vaccine candidate, mRNA-1273.211, demonstrated superior neutralizing titers compared to mRNA-1273 against all variants of concern, including Omicron; superiority was maintained for six months after booster for the Beta and Omicron variants Tolerability and safety of the bivalent booster were consistent with authorized 50 µg mRNA-1273 booster Moderna is evaluating an updated bivalent booster incorporating

CAMBRIDGE, MA / ACCESSWIRE / April 13, 2022 / Moderna, Inc. (NASDAQMRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, May 4, 2022 to report its first quarter 2022 financial results, and provide a corporate update. To access the live conference call, please dial 866-922-5185 (domestic) or 409-937-8950

CAMBRIDGE, MA / ACCESSWIRE / April 11, 2022 / Moderna, Inc., (Nasdaq:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that Jorge Gomez will join Moderna as Chief Financial Officer, effective Monday, May 9, 2022. He will serve on Moderna's Executive Committee and report to Chief Executive Officer, Stéphane Bancel. "I am pleased to welcome Jorge to Moderna as our Chief Financial Officer

Both mRNA-1020 and mRNA-1030 target hemagglutinin and neuraminidase antigens, two major influenza surface glycoproteins that are essential across the viral life cycle CAMBRIDGE, MA / ACCESSWIRE / April 11, 2022 / Moderna, Inc. (NASDAQMRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the first participants have been dosed in the Phase 1/2 study of the Company's seasonal influenza vaccine

Collaboration to target bacterial and viral pathogens including HIV, SARS-CoV-2, antimicrobial-resistant pathogens, and tuberculosis NEW YORK, NY and CAMBRIDGE, MA / ACCESSWIRE / April 7, 2022 / Moderna, Inc., (NASDAQMRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and the nonprofit scientific research organization IAVI today announced a new collaboration to employ mRNA technology to meet the challenge of

Initial grants of approximately $5 million awarded to local and global nonprofits that support groups and causes disproportionately affected by COVID-19 CAMBRIDGE, MA / ACCESSWIRE / April 4, 2022 / Moderna, Inc. (NASDAQMRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the launch of the Moderna Charitable Foundation to promote public health, access to quality healthcare and educational

50 µg dose approved for all adults over 50 years of age and immunocompromised adults over 18 years of age CAMBRIDGE, MA / ACCESSWIRE / March 29, 2022 / Moderna, Inc. (NASDAQMRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for its amendment to the emergency use authorization (EUA) to allow for a second

- COVID-19 vaccine Phase 2/3 study in children 6 months to under 6 years has successfully met its primary endpoint with robust neutralizing antibody titers similar to adults. Moderna is moving forward with global regulatory submissions for mRNA-1273 for primary vaccination of children 6 months to under 6 years of age. - Moderna has initiated a submission to the FDA for emergency use authorization of mRNA-1273 in children 6 to under 12 years of

On-shore manufacturing facility based in Melbourne, Australia, expected to produce up to 100 million mRNA respiratory vaccine doses annually CAMBRIDGE, MA / ACCESSWIRE / March 23, 2022 / Moderna, Inc. (NASDAQMRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the finalization of a strategic partnership with the Australian Federal Government to establish a state-of-the-art, domestic mRNA

- Two 25 μg doses of mRNA-1273 in participants 6 months to under 6 years met primary endpoint with robust neutralizing antibody titers similar to adults mRNA-1273 was generally well tolerated in this age group - Although not a primary endpoint, statistically significant vaccine efficacy was observed during the Omicron wave that was consistent with the lower two-dose effectiveness against Omicron seen in adults - Moderna is moving forward

CAMBRIDGE, MA / ACCESSWIRE / March 21, 2022 / Moderna, Inc. (NASDAQMRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced a new supply agreement with the Swiss Federal Government for seven million doses of Moderna's COVID-19 booster vaccine for anticipated delivery in 2023 and an additional option of seven million doses for delivery in 2023 and 2024. These doses are in addition to the seven

CAMBRIDGE, MA / ACCESSWIRE / March 17, 2022 / Moderna, Inc. (NASDAQMRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has submitted a request to the U.S. Food and Drug Administration (FDA) for an amendment to the emergency use authorization (EUA) to allow for a fourth dose of its COVID-19 vaccine (mRNA-1273) in adults 18 years of age and older who have received an initial booster of

Announcement follows recent authorization of the Company's mRNA COVID-19 vaccine in Australia and the European Union for active immunization to prevent COVID-19 caused by SARS-CoV-2 in children aged 6-11 years. CAMBRIDGE, MA / ACCESSWIRE / March 17, 2022 / Moderna, Inc. (NASDAQMRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Health Canada has approved the use of Moderna's mRNA

CAMBRIDGE, MA / ACCESSWIRE / March 16, 2022 / Moderna, Inc. (NASDAQMRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced an agreement with the Ministry of Health, Labour and Welfare of Japan (MHLW) to supply Japan with an additional 70 million doses of Moderna's COVID-19 booster vaccine or an updated booster vaccine candidate, if authorized, for anticipated delivery in the second half of

CAMBRIDGE, MA / ACCESSWIRE / March 14, 2022 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the first participant has been dosed in a clinical trial of an experimental human immunodeficiency virus (HIV) trimer mRNA vaccine (mRNA-1574). "Developing a vaccine regimen that induces sustained protective levels of HIV neutralizing antibodies in humans has been

Moderna's Omicron-specific bivalent booster candidate (mRNA-1273.214) combines Moderna's Omicron-specific booster candidate (mRNA-1273.529) and the Moderna COVID-19 vaccine (mRNA-1273) Moderna expects to enroll approximately 375 participants in the U.S. CAMBRIDGE, MA / ACCESSWIRE / March 10, 2022 / Moderna, Inc. (NASDAQMRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the first

CAMBRIDGE, MA / ACCESSWIRE / March 10, 2022 / Moderna, Inc. (NASDAQMRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host its virtual Vaccines Day for analysts and investors at 8:00 a.m. ET on Thursday, March 24. Moderna's Vaccines Day will include presentations from management and key opinion leaders (KOLs) on Moderna's mRNA vaccines and key considerations for vaccine

Moderna announces commitment to advance vaccines targeting 15 pathogens identified as biggest public health risk by WHO and CEPI into clinical studies by 2025 Moderna launches mRNA Access, a new collaborative enabling researchers around the world to utilize Moderna's mRNA technology platform to pursue research in their own labs on emerging and neglected infectious diseases Moderna expands commitment to never enforce COVID-19 patents in the Gavi

Facility to manufacture drug substance with opportunity for fill/finish and packaging capabilities Moderna investing up to $500 million to produce up to 500 million doses each year for the African continent Moderna will invest in building mRNA capabilities in Africa CAMBRIDGE, MA / ACCESSWIRE / March 7, 2022 / Moderna, Inc. (NASDAQMRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that

The Americas Enterprise Solutions Hub will support the U.S., Canada and Latin America and is in addition to Moderna's International Enterprise Solutions Hub in Warsaw, Poland Atlanta selected due to accessibility of broad and diverse talent base Hiring plan targeting approximately 150-200 employees over 2 years CAMBRIDGE, MA / ACCESSWIRE / March 3, 2022 / Moderna, Inc. (NASDAQMRNA), a biotechnology company pioneering messenger RNA (mRNA)

CAMBRIDGE, MA / ACCESSWIRE / March 2, 2022 / Moderna, Inc. (NASDAQMRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in the following upcoming investor conferences: - Cowen 42nd Annual Health Care Conference on Wednesday, March 9th at 9:10 a.m. ET - Barclays Global Healthcare Conference on Tuesday, March 15th at 1:30 p.m. ET - Oppenheimer 32nd Annual Healthcare

Announcement follows CHMP's previous decision to adopt a positive opinion recommending marketing authorization for Moderna's COVID-19 vaccine to include adolescents 12 years of age and older. CAMBRIDGE, MA / ACCESSWIRE / February 24, 2022 / Moderna, Inc. (NASDAQMRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for

Q4 2021 revenues of $7.2 billion; GAAP net-income of $4.9 billion and GAAP diluted EPS of $11.29 Full year 2021 revenues of $18.5 billion; GAAP net-income of $12.2 billion and GAAP diluted EPS of $28.29 Moderna increased its 2022 signed advance purchase agreements to approximately $19 billion, with additional signed options of approximately $3 billion; numerous discussions ongoing with governments for the fall of 2022 and 2023 Moderna received

Moderna has a commercial footprint in 56 countries across the world through direct presence and distributors and plans expansion in ten additional markets in 2022 Moderna also supplies the Company's COVID-19 vaccine to 92 Gavi COVAX Advance Market Commitment (AMC) low- and middle-income countries through GAVI, the Vaccine Alliance agreement CAMBRIDGE, MA / ACCESSWIRE / February 22, 2022 / Moderna, Inc. (NASDAQMRNA), a biotechnology company

Endorsement to proceed given by the independent Data and Safety Monitoring Board based on preliminary Phase 2 safety and tolerability data Moderna expects to enroll approximately 34,000 participants in multiple countries RSV causes severe disease burden among older adults and young children; there is no approved vaccine to prevent RSV CAMBRIDGE, MA / ACCESSWIRE / February 22, 2022 / Moderna, Inc. (NASDAQMRNA), a biotechnology company

mRNA-1608 is a vaccine candidate against Herpes simplex virus (HSV) mRNA-1468 is a vaccine candidate against varicella-zoster virus (VZV) to reduce the rate of herpes zoster (shingles) mRNA-4359 is a new checkpoint cancer vaccine CAMBRIDGE, MA / ACCESSWIRE / February 18, 2022 / Moderna, Inc. (NASDAQMRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it is expanding its mRNA pipeline

CAMBRIDGE, MA / ACCESSWIRE / February 16, 2022 / Moderna, Inc., (NASDAQMRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Therapeutic Goods Administration (TGA) in Australia has granted provisional registration for the use of Moderna's mRNA COVID-19 vaccine, Spikevax, in a 50 µg dose, two-dose series, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in children

Announcement reinforces Moderna's commitment to Europe and vision as a global commercial enterprise, building on the recent announcement of expansion in the Asia-Pacific region Local commercial presence to be established in Belgium, Denmark, the Netherlands, Norway, Poland, and Sweden to support the delivery of mRNA vaccines and therapeutics CAMBRIDGE, MA / ACCESSWIRE / February 16, 2022 / Moderna, Inc., (NASDAQMRNA) a biotechnology company

Long-term agreement includes a series of investments to acquire new equipment and adapt the present ROVI drug product fill-finish facilities and production lines in Spain CAMBRIDGE, MA and MADRID, SPAIN / ACCESSWIRE / February 16, 2022 / Moderna, Inc. (NASDAQMRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Laboratorios Farmacéuticos Rovi, S.A. (BME: ROVI), a pan-European pharmaceutical company

Announcement reinforces Moderna's commitment to Asia and vision as a global commercial enterprise New subsidiaries to be established in Malaysia, Taiwan, Singapore, and Hong Kong; providing local presence to support the delivery of mRNA vaccines and therapeutics CAMBRIDGE, MA / ACCESSWIRE / February 15, 2022 / Moderna, Inc., (NASDAQMRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced plans

CAMBRIDGE, MA / ACCESSWIRE / February 9, 2022 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Juan Andres, Chief Technical Operations and Quality Officer, has been elected to the National Academy of Engineering (NAE), broadly recognized as one of the highest acknowledgments of achievement in the field of engineering. "We are delighted that the National Academy

CAMBRIDGE, MA / ACCESSWIRE / February 8, 2022 / Moderna, Inc. (NASDAQMRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced a new supply agreement with the government of Colombia for 10.8 million doses of Moderna's COVID-19 vaccine. These doses are in addition to 10 million doses supplied to Colombia in 2021. Under the terms of the agreement, Moderna expects to deliver one million doses in the

CAMBRIDGE, MA / ACCESSWIRE / February 3, 2022 / Moderna, Inc. (NASDAQMRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, February 24, 2022 to report its fourth quarter and full year 2021 financial results, and provide a corporate update. To access the live conference call, please dial 866-922-5184 (domestic) or

Approval based on a comprehensive submission package including efficacy and safety data approximately six months after second dose SPIKEVAX has received approval by regulators in more than 70 countries, including Canada, Japan, the European Union, the UK, Israel 807 million doses of Moderna's COVID-19 vaccine shipped globally in 2021; approximately 25% of those doses shipped to low- and middle-income countries CAMBRIDGE, MA / ACCESSWIRE /

Phase 1 trial aims to build on response seen in proof-of-concept trial CAMBRIDGE, MA and NEW YORK, NY / ACCESSWIRE / January 27, 2022 / IAVI, the nonprofit scientific research organization, and biotechnology company Moderna announced today that first doses have been administered in a clinical trial of experimental HIV vaccine antigens at George Washington University (GWU) School of Medicine and Health Sciences in Washington, D.C. The Phase 1

Phase 2 study of Omicron-specific booster candidate (mRNA-1273.529) will include two cohorts: one including participants who received the two-dose primary series of mRNA-1273 and another including participants who received the two-dose primary series and a 50 µg booster dose of mRNA-1273 Omicron neutralization six months after the third 50 µg dose of mRNA-1273 declined, but remained detectable in all participants CAMBRIDGE, MA /

807 million doses of Moderna's COVID-19 vaccine shipped globally in 2021; approximately 25% of those doses shipped to low- and middle-income countries Product sales for 2021 approximately $17.5 billion (unaudited) Increasing APAs for 2022 delivery to approximately $18.5 billion and approximately $3.5 billion in options Announcing a new collaboration with Carisma Therapeutics for in vivo chimeric antigen receptor monocyte (CAR-M) therapeutics

Collaboration will combine Carisma's engineered macrophage technology with Moderna's mRNA and LNP technologies to generate and develop in vivo CAR-M therapeutics Multi-year research collaboration funded by Moderna with options for up to twelve targets Carisma to receive $45 million up-front cash payment and investment by Moderna in the form of a $35 million convertible note Carisma eligible to receive milestone and royalty payments CAMBRIDGE,

Moderna expects to enroll approximately 270 participants in the U.S. EBV is a major cause of infectious mononucleosis, which can debilitate patients for weeks to months; there is no approved vaccine to prevent EBV EBV can also lead to lifelong medical conditions and is associated with an increased risk of developing multiple sclerosis, certain lymphoproliferative disorders, cancers, and autoimmune diseases Moderna now has a portfolio of two

CAMBRIDGE, MA / ACCESSWIRE/ January 4, 2022 / Moderna, Inc. (NASDAQMRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that CEO Stéphane Bancel will participate in a fireside chat at the Goldman Sachs 14th Annual Healthcare CEOs Unscripted Conference on Thursday, January 6th at 2:00 p.m. ET. A live webcast of the presentation will be available under "Events and Presentations" in the

CAMBRIDGE, MA / ACCESSWIRE / January 3, 2022 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that CEO Stéphane Bancel will present an update on the Company and its pipeline of mRNA development programs at the virtual 40th annual J.P. Morgan Healthcare Conference on Monday, January 10th at 8:15 a.m. ET. A live webcast of the presentation will be available

Agreement includes 15 million doses for delivery in the third quarter of 2022 and 5 million doses for delivery in the fourth quarter of 2022 CAMBRIDGE, MA / ACCESSWIRE / December 27, 2021 / Moderna, Inc. (NASDAQMRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced a revised supply agreement with the government of South Korea for 20 million doses of Moderna's COVID-19 vaccine or an updated

Total of 27.5 million doses ordered by the Swiss Federal Government to date CAMBRIDGE, MA / ACCESSWIRE / December 27, 2021 / Moderna, Inc. (NASDAQMRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Swiss Federal Government has exercised its option to purchase an additional seven million doses of Moderna's booster vaccine for delivery in the second half of 2022. These doses are in

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced preliminary neutralizing antibody data against the Omicron variant following the Company’s booster candidates at 50 µg and 100 µg dose levels. The currently authorized 50 µg booster of mRNA-1273 increased neutralizing antibody levels against Omicron approximately 37-fold compared to pre-boost levels and a 100 µg dose of mRNA-1273 increased neutralizing antibody levels approximately 83-fold compared to pre-boost levels.

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced an agreement in principle with the Australian Government to build a state-of-the-art messenger RNA (mRNA) vaccine manufacturing facility in Victoria, Australia including access to Moderna’s mRNA development engine. The contemplated framework would build the foundation to support Australia with direct access to rapid pandemic response capabilities and to provide access to Moderna’s vaccines in development for respiratory viruses. Moderna and the Australian government are committed to finalize the agreement.

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced an amendment to its existing contract with Gavi, the Vaccine Alliance, to accelerate supply of 20 million doses to COVAX by December 31, 2021 for a total of 54 million doses made available to COVAX in 2021. Deliveries to COVAX Advance Market Commitment (AMC) countries have already begun.

Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the first positive interim data from the Phase 1 study of the Company’s quadrivalent seasonal flu vaccine candidate, mRNA-1010. In the study, mRNA-1010 successfully boosted hemagglutination inhibition (HAI) assay geometric mean titers against all strains 29 days after vaccination at all doses tested in both younger and older adults. The Company also announced that the Phase 2 study of mRNA-1010 is now fully enrolled and preparation for the Phase 3 study is underway. Moderna also provided an update on its seasonal flu vaccine program including the announcement of two beyond quadrivalent seasonal flu development candidates (mRNA-1011 and mRNA-1012).

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced it will host a live conference call and webcast on the Phase 1 interim analysis of its seasonal influenza vaccine candidate, mRNA-1010 tomorrow, Friday, December 10, 2021 at 8:00 a.m. ET.

Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the launch of its Artificial Intelligence (AI) Academy, an innovative initiative that will bring to life an immersive learning experience for Moderna employees, in partnership with Carnegie Mellon University (CMU).

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced a revised supply agreement with the UK government for up to 60 million doses of Moderna’s COVID-19 vaccine, which may include authorized booster vaccine candidates, with up to 29 million doses expected to be delivered in 2022 and up to 31 million doses expected to be delivered in 2023. Under the agreement, the UK government retains a right to increase its purchases in 2022 and 2023 by up to 20% above the contracted volumes, or to decrease by the same amount.

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in the following upcoming virtual investor conferences: